One such example is the DARPins generated against HER2; these displayed higher specificity and similar sensitivity when compared to FDA-approved antibodies for the in situ identification of HER2 expression status in FFPE breast cancer tissue (113). This evidence concerns the gene ERBB2 and breast cancer.